ABSTRACT: Originally discovered almost a century ago, cocrystals continue to gain interest in the modern day due to their ability to modify the physical properties of solid-state materials, particularly pharmaceuticals. Intensification of cocrystal research efforts has been accompanied by an expansion of the potential applications where cocrystals can offer a benefit. Where once solubility manipulation was seen as the primary driver for cocrystal formation, cocrystals have recently been shown to provide attractive options for taste masking, mechanical property improvement, and intellectual property generation and extension. Cocrystals are becoming a commercial reality with a number of cocrystal products currently on the market and more following in registration and clinical trial phases. Increased commercialization of cocrystals has in turn necessitated additional research on methods to make cocrystals, with particular emphasis placed on emerging technologies that can offer environmentally attractive and efficient options. Methods of producing cocrystals and of harnessing the bespoke physical property adjustment provided by cocrystals are reviewed in this article, with a particular focus on emerging trends in these areas.
INTRODUCTION
Cocrystals are solids that are neutral crystalline single phase materials composed of two or more different molecular and/or ionic compounds generally in a stoichiometric ratio which are neither solvates nor simple salts. 1 If at least one of the coformers is an API and the other is pharmaceutically acceptable, then it is recognized as a pharmaceutical cocrystal. 2 Cocrystals of different stoichiometry with the same coformer are possible, as illustrated by the carbamazepine:4-aminobenzoic acid cocrystal system, which can exist in 1:1, 2:1, and 4:1 stoichiometric configurations. 3 A cocrystal has a different crystal structure to either of the starting materials and as a result different physicochemical properties. Cocrystals are attractive because the cocrystal solid can be designed to have superior physical properties to either of the pure starting molecules. Physical property improvement via cocrystal formation has been demonstrated for solid explosives, 4 agrochemicals, 5 pigments, 6 and, particularly, pharmaceuticals. 7−12 Physical property improvement is of particular interest to pharmaceuticals as the vast majority of medicines are delivered as solid forms. The physical properties of the solids contained within a pharmaceutical drug product will have a direct impact on the processing, delivery, and, ultimately, performance of the medicine. To provide a classic example, crystal structure directly affects the solubility of a given solid in solution. Drug products require a certain solubility to be bioavailable in the body. It is estimated that 40% of existing drug products and up to 90% of new chemical entities have limited aqueous solubility 13 and hence cannot be delivered to the body using conventional techniques. Cocrystal formation with a suitable coformer offers the potential of improved solubility via modification of the underlying crystal structure, thus potentially rendering the compound bioavailable. As cocrystal research has expanded, it has available a range of application areas for physical property manipulation through cocrystal formation. Improvements in solubility, stability, bioavailability, and mechanical properties have been well documented, 14, 15 and emerging applications such as taste masking and intellectual property extension are being explored.
Research in cocrystal structure and applications has shown an exponential increase in the past decade, evident in the number of cocrystal structures deposited in the Cambridge Structural Database 16 and cocrystal related patent applications. In light of this, it is surprising that cocrystal preparation methods have remained, until relatively recently, largely poorly defined. Limited research attention has been directed specifically at cocrystal preparation, and this topic receives little detail in the majority of existing publications. Initial cocrystal related research efforts centered on elucidation of the crystal structure of cocrystal and bonding mechanisms, requiring high quality single crystals from cocrystal samples. This was typically achieved using trial and error approaches based on solvent evaporation that serendipitously yielded cocrystals, on occasion. A universal approach was lacking. As experimentation with cocrystal systems increased, the demand for larger quantities of cocrystal material accompanied it. Solution based cocrystallization routes were employed, requiring knowledge of the solubility of both starting materials in the solvent of choice, often supplied in the format of a ternary phase diagram. Again, methods used were inconsistent from research paper to research paper, and no universal approach was practiced.
Today, a wide range of successful cocrystal preparation methods have been documented: solvent evaporation, solid state grinding, solution crystallization, slurry conversion, melt crystallization, hot melt extrusion, and spray crystallization. But, there is little consistency in the application of different preparation methods or even in the terminology used to describe the same. Details such as solvent choice, concentration of the target molecule/coformer, equilibration time, and the recovery process are often not provided. This makes it difficult to repeat or compare cocrystal preparation methods and must be confusing to a newcomer to this research area. 16 The objective of this review is to systematically describe all reported cocrystal preparation routes and applications in a single location in an effort to standardize progress achieved todate in this evolving area.
COCRYSTAL PRODUCTION
Cocrystal production routes can be broadly categorized as solid-state or solution based. Solid-state methods can be differentiated as methods using very little or no solvent, with solution based methods representing production routes that involve a large excess of solvent necessitating a subsequent isolation stage to separate the crystalline product from the mother liquor.
2.1. Solid State Methods. 2.1.1. Contact Formation. The spontaneous formation of cocrystals via mixing of pure API and coformer under a controlled atmospheric environment has been reported. 17−19 In this method, no mechanical forces are applied during cocrystallization. 20, 21 However, in some cases, brief grinding of pure components individually before mixing has been done. 20 Rodriguez-Hornedo et al. studied the effect of premilling of the starting materials on the cocrystallization rate of carbamazepine and nicotinamide. 20 It was shown that the cocrystallization rate in the case of premilled reactants was markedly faster than that of unmilled reactants (12 versus 80 days, respectively). Moreover, higher cocrystallization rates have been reported for the same system at higher temperatures and relative humidity, regardless of the mechanical activation. 20 Sarcevica et al. reported the formation of an isoniazidbenzoic acid cocrystal via spontaneous cocrystallization. 22 They reported that the rate of reaction was considerably increased at higher premilling frequencies of the pure reactants. 22 Moreover, Ibrahim et al. studied the effect of the particle size of starting materials on spontaneous cocrystallization of urea and 2-methoxybenzamide (2-MB). It has been shown that smaller particle size distributions lead to faster cocrystal formation. A rapid increase in cocrystallization rate was observed in the case of the small particle size distribution of 20−45 μm, where no buried eutectic or amorphous intermediate phase was detected. 21 The mechanism of cocrystallization in the presence of moisture at deliquescent conditions consists of three stages of (1) moisture uptake, (2) dissolution of reactants, and (3) cocrystal nucleation and growth 23 ( Figure 1 ).
Berry et al. used hot-stage microscopy for cocrystal screening. They used the Kofler method to successfully probe the binary phase behavior of a given cocrystal system, revealing potential cocrystal phases in five API mixtures. In this work, nicotinamide was chosen as a molecular scaffold former with a series of APIs, e.g., fenbufen, flubiprofen, ibuprofen, ketoprofen, and salicylic acid. In this method, one component is melted then allowed to solidify, before another component is brought into contact with it and a proportion of the first component is solubilized. Thus, after recrystallization of all materials, a zone of mixing is created. This is comparable to the binary phase diagram of the two components. With this method, they were able to identify the formation of nicotinamide:ibuprofen, nicotinamide:salicylic acid, nicotinamide:flubiprofen, and nicotinamide:fenbufen.
2.1.2. Solid State Grinding. Solid state grinding methods have been used successfully to generate cocrystal powder samples. Two formats are practiced: neat (dry) grinding and liquid assisted grinding. Neat grinding involves the combination of the target molecule and coformer in their dry solid forms with the application of pressure through manual (mortar and pestle) or mechanical (automated ball mill) means. Dry grinding is distinct from melt crystallization as the solid starting materials are not expected to melt during grinding. The temperature achieved during grinding is often monitored to ensure the same, and will often be reported. Two sulphathiazole:carboxylic acid cocrystals were prepared by grinding stoichiometric equivalents of sulphathiazole with the required carboxylic acid for 90 min in a Retsch mixer mill at a 25 Hz frequency with the temperature not allowed to exceed 37°C. 24 There is an efficiency associated with solid state grinding, relative to solution based methods, in that yield is not lost to the solvent due to solubility. 25 Issues with dry grinding can include failure to form a cocrystal, incomplete conversion to the cocrystal, and crystalline defects with possible generation of some amorphous content. Incomplete conversion to the cocrystal, resulting in a mixture of cocrystals and excess starting material in the product, is not desirable as it requires the use of addition purification steps to yield a pure cocrystal product. Increasing the grinding time can sometimes resolve this, but product mixtures can also be an indication of nonstoichiometric cocrystal formation. Dry grinding is typically attempted with stoichiometric mixtures of target and coformer solids. This requires formation of a stoichiometric cocrystal to consume all available starting materials. Formation of a nonstoichiometric cocrystal will thus lead to an excess of either remaining material. Ideally, dry grinding should be completed using molar equivalents and an excess of each starting material. This will also facilitate discovery of alternative cocrystals if they exist for a system.
Liquid assisted grinding involves the addition of a solvent, typically in a very small amount, to the dry solids prior to the initiation of milling. The solvent has a catalytic role in assisting cocrystal formation and should persist for the duration of the grinding process. More efficient cocrystal formation is suggested for liquid assisted methods than with neat methods, with a tendency for the cocrystal formation kinetics to increase as the solvent added to the grinding media is increased, 26 but as yet this is inconclusive. The liquid component is thought to accelerate reaction kinetics by wetting the solid surface. Liquid assisted grinding has been reported in a number of different formats. Trask et al. applied caffeine and maleic acid to make a caf:ma cocrystal for the first time using neat and liquid assisted grinding (LAG) methods. Their research suggested that a 1:1 or 2:1 caf:ma cocrystal could be manufactured after 30 and 60 min of grinding depending on the solvent selection. 27 But in 2010, another method (ultrasound assisted solution cocrystallization) was presented to form a purer cocrystal of caf:ma, because the synthesized cocrystals by Trask et al. contained impurities and were accompanied by different amounts of caffeine. 28 Benzoic acid cocrystals were formed by wetting an equimolar mixture of benzoic acid and the carboxylic acid coformer in a mortar with methanol and grinding it to dryness. 29 A total of 50 μL of nitromethane was added to an equimolar mixture of caffeine and tetrafluorosuccinic acid with grinding for 30 min at 30 Hz to form a 1:1 cocrystal; the same method for a 2:1 mixture of caffeine and octafluoroadipic acid yielded a 2:1 cocrystal. 30 A total of 10 μL of ethanol or nitromethane facilitated the formation of a 2:1 cocrystal from a 2:1 molar mixture of pterostilbene and piperazine, whereas 10 μL of toluene of 2-propanol facilitated the formation of a 1:1 cocrystal from a 1:1 molar mixture of pterostilbene and glutaric acid. 31 For generating highly water-soluble cocrystals of a poorly soluble nutraceutical Hesperetin (HESP), the solvent drop grinding cocrystallization method was applied. Chadha et al. used different coformers such as picolinic acid (PICO), nicotinamide (NICO), and caffeine (CAFF). Their research has led to optimization of the pharmacokinetic properties by improving the bioavailability. Also, the dissolution of prepared cocrystals in an aqueous buffer showed that the hesperetin concertation is around 4−5 times higher than that of the pure one 32 ( Figure 2) . A wide range of carbamazepine cocrystals was generated using solvent drop grinding and solvent evaporation in a screening exercise by Weyna et al., and equivalent cocrystal hits were achieved from either method. 33 In general, there is no clear logic proposed for solvent selection for liquid assisted grinding experiments, with limited justification for solvent choice provided in the existing literature.
2.1.2.1. Cocrystallization Mechanisms. It has been suggested that the synthesis of new cocrystals is affected by many variables, which are mostly affected by the nature of solvent and the reactants. For example, the presence of functional groups and the solubility of reactants in the solvent in addition to many experimental conditions such as the stoichiometric ratio of the coformer and API, temperature, stirring, pH, and type of glassware are just a few of the effective parameters. 34 On the other hand, the rules of hydrogen bonding, synthons, and graph sets could be helpful in designing cocrystal systems. For instance, for an API containing carboxylic acid, choosing coformers containing acidic moieties or amides could increase the chance of cocrystallization. 35 However, there is no guarantee for cocrystal formation. Thus, preparation of cocrystals is often a multistage and empiric process.
As described above, many techniques are capable of cocrystal synthesis. However, the lack of control over the nucleation, crystallization, and phase evolution of the cocrystals is still a significant scientific challenge. 36 Mechanochemical techniques are promising techniques for cocrystal production from a green chemistry and affordable synthetic pathway. 37 For the first time in 1893, grinding was used as one of the main techniques for cocrystal formation in order to produce quinhydrone cocrystals from equimolar amounts of pbenzoquinone and hydroquinone. 38 Since then, many other crystalline compounds have been formed through both mechanisms of neat and wet grinding. Despite all the technological improvements in the field, the underlying mechanism(s) of cocrystal formation through these methods has not been understood fully. Thus, many efforts have been put into understanding the underlying mechanism of these techniques. Fox has proposed the formation at very high temperatures of around 1000°C for a short period on the order of milliseconds. 39 Balaź̌has proposed the magma-plasma model which considers the formation of transient plasma at temperatures up to 10 000°C to activate the reaction. 37, 40 However, no explanation is provided for the stability of the coformer and API at these high temperatures.
Cocrystallization is not a single mechanism process, as Jones and Frisčǐćhave mentioned, 41 but rather a series of mechanisms which include molecular diffusion, eutectic formation, 42 and cocrystallization through an amorphous phase. 43 The common point in these three mechanisms is the presence of an intermediate bulk phase (gas, liquid, or amorphous solid) with improved mobility and/or higher energy of reactant molecules with respect to the starting crystalline forms.
For each one of these mechanisms, there are examples in the literature. It has been mentioned that molecular diffusion is more likely in cases where one or both reactants have significantly high vapor pressures in the solid state. The availability of fresh surfaces enhances the molecular diffusion on the reactant crystals. 44 Additionally, it has been suggested that mechanical force beaks down the intermolecular bonds of the crystals of the reactant molecules. 44 Figure 3 shows the schematic of the cocrystal formation mechanism via grinding. The solid and vapor diffusion are both significant in some cases of cocrystallization, e.g., in cocrystals containing naphthalene. However, in heavier aromatic hydrocarbons, surface diffusion is a more effective mechanism of cocrystal formation.
In liquid phase assisted cocrystallization, the formation of solid cocrystals is assisted by an intermediate liquid phase, e.g., when one of the reactants is liquid at ambient conditions. 45−47 Eutectic formation in cocrystal synthesis is also an increasingly significant mechanism in cocrystal formation. 48 The cocrystal formation at the interface of two colorless crystals of diphenylamine and benzophenone was revealed by microscopic observation, where the contact surface was converted into liquid. Incorporating grinding with eutectic-mediated cocrystallization enhances the process through two mechanisms: first, increasing the fresh reactant surfaces for eutectic formation and, second, improving the cocrystal nucleation in the eutectic phase. 41 In cases where there is no special mass transfer pathway (i.e., liquid or gas phase), cocrystallization can take place through the formation of amorphous intermediates. This is possible in cocrystallization of molecular solids with strong intermolecular interactions (e.g., hydrogen bonds). Moreover, it has been reported that grinding at temperatures below the glass transition temperature of the reactants results in amorphous phase formation; however, grinding at higher than that would lead to metastable polymorphic forms. 49 In liquid assisted grinding, the mechanism of cocrystal formation has not been completely understood yet. In some cases, it has been suggested that liquid just plays the role of lubricant by providing a medium to facilitate the molecular diffusion. 41 Since the cocrystals formed after neat and liquid assisted grinding are typically thermodynamically stable, the low solvent fraction during liquid assisted grinding is of little significance in controlling the outcome of the process. The same rationale behind the liquid assisted grinding can be applied to slurry cocrystallization as well. Moreover, the nature of the liquid phase used in grinding can be significantly influential during mechanochemical cocrystallization. 50 The mentioned mechanisms are the ones mostly involved with mechanochemical synthesis of cocrystals. As HME is a mechanochemical method of processing, each one of these mechanisms could be valid depending on the initial reactants, mechanical forces, temperature, and liquids used during the process.
2.1.3. Extrusion. Distinct from Hot Melt Extrusion (HME), Twin Screw Extrusion (TSE) operates at temperatures below the melting point of either starting material and takes place in a distinct piece of equipmentan aptly named twin screw extruder. This unit consists of two co-/counter-rotating screws in a single barrel. Screw action provides simultaneous mixing and movement of material along the length of the barrel. Daurio et al. reported on the formation of four model cocrystals using a 16 mm twin screw extruder with four controllable temperature zones. 51 Carbamazepine:saccharin, theophylline:citric acid, caffeine:oxalic acid, and nicotinamide:cinnamic acid cocrystals were prepared by passing stoichiometric blends of the dry powder of each starting material through the extruder. The impact of temperature on conversion to a cocrystal was specific to the cocrystal system being studied, with no apparent temperature dependence for cocrystals of carbamazepine:saccharin and a strong temperature dependence for nicotinamide:cinnamic acid. In a separate study, the same authors compared an AMG-157:saccharin cocrystal prepared from TSE and solution crystallization. 52 Cocrystals from TSE were shown to have improved surface area, bulk density, and flow properties relative to those produced from solution crystallization.
In another case study, carbamazepine-trans-cinnamic acid cocrystals were extruded by both Single Screw Extrusion (SSE) and TSE. According to the DSC and XRD results, less crystallinity was observed for cocrystals which were manufactured via a single screw extruder compared to a twin screw extruder. Moreover, the dissolution rate of the TSE cocrystal was higher than that of the SSE one. 53 Medina et al. applied the TSE method for the first time to manufacture cocrystals of caffeine and AMG 517. Their research proved that TSE helps to have a highly efficient mixing and close material packing, which leads to improvement of surface contact between cocrystal components. Consequently, cocrystal formation will be facilitated without adding any solvent. 54 Twin screw extrusion also was employed to manufacture ibuprofen−nicotinamide cocrystals as a continuous process. Off-line PXRD demonstrated the purity of the cocrystal to be variable between 20% and 99% with different extrusion conditions. This study showed that extrusion temperature, screw configuration and screw rotation speed are the three critical parameters to determine cocrystal purity. The optimum situations to reach the purest ibuprofen−nicotinamide cocrystal are the highest residence time (lowest speed) and highest processing temperature with the most intensive mixing screw. 55 2.1.4. Hot Melt Extrusion. Hot melt extrusion (HME) is a relatively recent addition to cocrystal preparation options. This specialist technique combines simultaneous melting and mixing of the target molecule and coformer via the use of a heated screw extruder ( Figure 4) . Typically, the starting materials are mixed in a molar ratio and fed to the heated extruder. Melting occurs, facilitating intimate mixing of the starting materials. The cocrystal nucleates directly in the melt, and pure cocrystal extrudate is isolated from the extruder continuously. The advantages of the method are elimination of the use of organic solvents, fast operating times, increased conversion relative to solution based methods, reduced waste, and the technology lending itself well to continuous pharmaceutical processing. Moradiya et al. described the production of carbamazepine:cinnamic acid cocrystals using a single screw and twin screw extruder. 56 Cocrystals obtained from the twin screw extruder displayed enhanced dissolution properties relative to those obtained from the single screw/ solution based methods. Melt extrusion as a continuous manufacturing technique was employed to produce indomethacin−saccharin cocrystals. Their studies proved that the temperature profile, feed rate, and screw speed were the three critical process parameters (CPP), which are needed for the engineering of high quality cocrystals. Moreover, they showed that temperature has no impact on the dissolution rate of cocrystals. 57 However, this is only valid in this case where the samples have the same crystallinity based on Rietveld analysis. It has been reported that in the case of deviation in the crystalline quality by process temperature, the dissolution rate will be affected subsequently. In contrast, the particle size of cocrystals can have an influence on their dissolution profile. 58, 59 Dhumal et al. manufactured the agglomerated cocrystal of ibuprofen and nicotinamide by hot melt extrusion. They have studied the effect of different processing parameters such as screw speed, temperature profile, and screw configuration. It was depicted that for cocrystallization to happen, the barrel temperature must be above the eutectic point of physical mixture. Also, in order to get the purer cocrystal, the highest sheer screw configuration should be applied. 60 Additionally, it was shown that incorporating the polymeric matrix of xylitol in the manufacturing of the ibuprofen− isonicotinamide cocrystal has a significant impact on the torque of extrusion and the residence time. They studied the effect of adding 10%, 30%, and 50% xylitol as a polymer. It has been observed that with increasing the amount of xylitol, the torque decreased and hence the residence time increased. 61 Liu et al. also selected carbamazepine (CBZ) and nicotinamide (NIC) as a model drug and coformer, respectively, to manufacture an amorphous CBZ-NIC cocrystal solid dispersion via the HME method. The main scope of their study was to show cocrystallization as a considerable approach to prevent thermal degradation of heat sensitive drugs during HME. First, they proved that CBZ and NIC could in situ cocrystallize in PVP/VA during the process of heating in hot melt extrusion. The newly formed cocrystal completely melted around 160°C. This temperature is 30°C lower than the T m of CBZ. Hence, the CBZ-NIC-polymer solid dispersion could be successfully prepared while preserving heat sensitive API from thermal degradation via HME. 62 2.1.5. High Shear Wet Granulation. Typically employed for drug product formulation, high shear wet granulation has been investigated as a route to cocrystal preparation. This technique involves the agglomeration of powder particles via a liquid medium in the presence of a binder. Technically, the procedure is carried out in a high shear granulator, which imparts shear on the powder mixture through impellers and choppers. The mechanism of cocrystal formation by high shear granulation is not exactly known but suspected to be either similar to liquid assisted grinding or slurry transformation. Granules containing a 1:1 piracetam:tartaric acid cocrystal were successfully produced from a mixture of piracetam, tartaric acid, and a variety of excipients in the presence of water using a Bohle mini granulator. 63 The extent of cocrystal formation was impacted by the volume of granulation liquid used, impeller speed, and the excipient mixture used, with 95% conversion achieved within 5 min.
In another case study, Sladkováet al. studied the vabradine hydrochloride (S)-mandelic acid 1:1 cocrystal (IClSM) and the effect of adding two different granulation liquids. First, lactose monohydrate was added as a common formulation filter to the mixture of API and coformer. Then, water and ethanol were applied to granulate it. The results showed that no cocrystal formation was observed when water was applied for granulation in the presence of lactose monohydrate, while by adding ethanol the cocrystal was formed and PXRD depicted the cocrystal characteristic peaks. 64 
Solution Based Methods.
A variety of methods exist to cocrystallize from solution, and each will be discussed in the subsequent section. At the outset, it is worthwhile considering some universal solution crystallization concepts. The driving force for crystallization is supersaturation, the difference between the actual experimental concentration and the reported solubility concentration at that temperature in that solvent. With a cocrystal system, there are two concentrations to consider, that of the target molecule and that of the coformer. The concentrations of both relative to the solubility of the cocrystal (most accurately expressed in terms of target molecule and coformer) dictate the supersaturation for cocrystallization. A eutectic point will exist where at one fixed solution concentration, a mixture of cocrystal and the target molecule is the stable solid phase for the system; a second eutectic point exists for a mixture of the cocrystal and coformer. The eutectics represent solution minima where the solvent content is at its lowest value, meaning solubility is at its highest value. The cocrystal will only be stable, less soluble than target molecule or coformer, at concentrations lying between the eutectic points. Knowledge of this concentration range, termed the cocrystal operating range, is key to designing a successful solution cocrystallization. Operation outside of this range can fail to yield a cocrystal or can yield a cocrystal/target molecule or cocrystal/coformer mixture in the solid phase. The solubility of a cocrystal system is most accurately represented in a ternary phase diagram (TPD). This triangular diagram illustrates the solubility of the solid phases in a given solvent at a fixed temperature and pressure and also identifies regions of stability for different solid phases in the system. 65, 66 Figure 5 shows the typical ternary phase diagrams which describe the three-phase behavior of a multicomponent system: API, coformer, cocrystal, and solvent. It is also able to predict the pathway of cocrystal formation.
Crystallization from solution is an established unit operation for single component crystallizations, and one would imagine that this technique has the greatest industrial potential for upscaling cocrystal preparation without moving toward the specialist techniques.
Screening cocrystal systems via solution cocrystallization in combination with grinding approaches can significantly enhance the exploration of a variety of cocrystal systems. As an example, the potential of cocrystal formation of caffeine with dicarboxylic acids was investigated by the solution cocrystallization of caffeine/L-malic acid. 68 2.2.1. Evaporative Cocrystallization. Evaporative cocrystallization is a common method of generating cocrystals, typically employed for generating single crystal cocrystals suitable for diffraction studies to elucidate cocrystal structure. The technique involves the nucleation and growth of a cocrystal from a solution of both coformers in a solvent, with supersaturation provided by removal of the solvent from the solution via evaporation. Individual cocrystals, or the bulk crystal sample, should be harvested before the solution evaporates to dryness to ensure recovery of a clean crystal(s). A slow rate of evaporation is usually desired so as to ensure formation of a small number of larger crystals as opposed to a high number of smaller crystals. As crystal structure identification is a necessary step in the discovery of new cocrystal forms, evaporative cocrystallization is evident in the majority of cocrystal related research papers, and there are countless examples of it in the literature. It should be noted that identification of the crystal structure is a necessity for defining whether the obtained crystal is a cocrystal, salt, hydrate, or any other polymorphic form of the API or coformer. A classic example is provided by Basavoju et al. in the description of the generation of single crystals of a norflaxin-isonicotinamide cocrystal from chloroform: 0.1 mmol of norflaxin and 0.1 mmol of isonicotinamide are dissolved in 8 mL of chloroform. The chloroform was subsequently allowed to evaporate at room temperature, yielding rod shaped single crystals of a 1:1 norfloxacin:isonicotinamide cocrystal. 10 Another example of making cocrystals with the solvent evaporation method was shown by Chow et al. for ibuprofen−nicotinamide and flurbiprofen−nicotinamide cocrystals, which exhibited higher intrinsic dissolution rates compared to the corresponding profens. Moreover, the synthesized cocrystals presented higher tabletability and less absorbed humidity compared to the individual precursors. 69 This method is typical in that most evaporative cocrystallizations are performed in stoichiometric solutions, typically a 1:1 molar ratio of precursors. However, this is not recommended as it tends to only yield stoichiometric cocrystals and will not identify cocrystals with unequal API/ coformer ratios when they do exist for a cocrystal system. Ideally, evaporative cocrystallization should be performed from three solutions: 1:1 stoichiometric solution, a solution where 70 Not only will this increase the probability of obtaining a cocrystal, it will also identify cocrystals with unequal API/coformer ratios where they are possible. In studies to date, there is limited attention given to the role of the solvent in evaporative cocrystallization.
In theory, there is no reason why evaporative cocrystallization could not be used at larger scales to produce bulk amounts of cocrystal products. In this case, single crystal formation would not be required, and the cocrystallization could be optimized the same as any crystallization process. At lab scale, evaporative cocrystallization tends to occur from very dilute solutions. This is oftentimes due to a lack of solubility information on the precursor molecules in the solvent but can also be a purposeful attempt to reduce the rate of supersaturation to promote the formation of larger crystals. Optimization of these starting concentrations and process conditions could design an efficient large scale evaporative cocrystallization. In practice this could be difficult to operate and control, possibly leading to the preferred selection of alternative cocrystallization routes at larger scales.
Depending on the volatility of the solvent, evaporative cocrystallization can be very slowevaporation times of up to six months have been reported. 71 While slow evaporation is desirable to generate single crystals, extended evaporation times are a hindrance to progress. Various techniques can be used to accelerate the rate of evaporation during evaporative cocrystallization, with the aim of decreasing the process time required to yield cocrystals. Elevated temperature has been employed, where evaporation of methanol from a stoichiometric solution of ezetimibe and methyl paraben in methanol was conducted at 35°C using a water bath. Evaporation (to dryness) of an unspecified organic solvent from a solution of curcumin and phloroglucinol was achieved under a vacuum using a rotary evaporator at 60°C to generate a powder cocrystal sample. 72 
Cooling Crystallization.
A designed seeded cooling crystallization was used to prepare cocrystals of carbamazepine:nicotinamide from ethanol, in an effort to establish a scalable solution cocrystallization strategy. 73 Solvent selection, identification of the thermodynamically stable cocrystal operating range, and desupersaturation kinetics were considered in design of the process, which was demonstrated at 1 L scale with 90% yield and 14 L kg −1 throughout. A similar approach was taken by Holaňet al. in the preparation of agomelatine:citric acid cocrystals, and the impact of cooling rate and seed amount on the crystal size distribution in the final product was assessed. 74 2.2.3. Reaction Cocrystallization. Reaction cocrystallization was used to produce cocrystals of carbamazepine:saccharin by combining individual feed solutions of either of the starting materials. 75 The method was informed by the ternary phase diagram and illustrated a robust operating range for cocrystal formation and demonstrated the expected relationship between supersaturation and induction time. Formation of a carbamazepine:nicotinamide cocrystal was also done by reaction cocrystallization under ambient conditions. 76 
Isothermal Slurry Conversion.
This technique involves the suspension of the target molecule and coformer, usually in a fixed molar ratio, in a solvent with the solid fraction always remaining in excess. In practical terms, the technique can also operate by adding the target molecule to a solution or suspension of coformer in solvent. While this is a solution based method, it does not require generation of a clear (fully dissolved) starting solution, as is the case with the previous methods described above.
The rate at which slurry conversion occurs will differ based on the solubility driving force, the relative concentrations of the target molecule and coformer, and the nucleation and growth kinetics of the system. There have been
; pure carbamazepine persisted. The same experiment at 0.6 M 4-ABA yielded the 2:1 cocrystal, and with excess 4-ABA present, the 1:1 cocrystal was formed. This relates to the position of the experimental composition on the ternary phase diagram, again reflecting the importance of a well-defined ternary phase diagram for a cocrystal system. The yield and productivity of isothermal slurry conversion can vary widely based on the operating conditions and concentrations and can also be optimized through use of the TPD. 77 Cheney et al. showed that 96% cocrystal yield was achieved for a slurry conversion of meloxicam with aspirin in 3 mL of tetrahydrofuran (THF) at ambient conditions overnight. 78 Croker and Rasmuson demonstrated the purity and process efficiencies that can be achieved with isothermal slurry conversion for the toluenesulphonamide:triphenylphosphine oxide cocrystal system. 79 Although the slurry conversion method typically requires a greater amount of starting materials and will incur some material loss due to residual solubility in the solvent, it is considered one of the most promising screening techniques due to its high efficiency.
2.3. Supercritical Fluid Methods. Cocrystals have been successfully produced using supercritical fluid technology, primarily with the use of supercritical carbon dioxide (CO 2 ), by three different approaches which focus on distinct supercritical CO 2 properties: solvent, antisolvent, and atomization enhancement. 80 2.3.1. Cocrystallization with Supercritical Solvent. The Cocrystallization with Supercritical Solvent (CSS) technique uses the solvent power of supercritical CO 2 to suspend the API and the coformer as a slurry in liquid or supercritical CO 2 , avoiding the use of toxic organic solvents. 81 By controlling the thermodynamic conditions of CO 2 (e.g., temperature, pressure), it is possible to fine-tune its density and solvent power, which provides control over the cocrystallization between cocrystal components. Subra-Paternault et al. have compared the cocrystallization outcome of distinct APIs (e.g., indomethacin, theophylline, carbamazepine, caffeine, sulfamethazine, and acetylsalicylic acid) with saccharin in liquid and supercritical CO 2 . 82 Those authors have suggested that despite the usual low solubility of most cocrystal components (API and coformer) in CO 2 , cocrystallization is mediated by their dissolution in it. In particular, they have observed that by increasing the concentration of the cocrystal components in Crystal Growth & Design Cryst. Growth Des. XXXX, XXX, XXX−XXX the CO 2 phase, the cocrystallization rate is increased. In addition to this, stirring of the cocrystal components in the CO 2 slurry promotes intense mass transfer by convection, which was found to be paramount to achieving complete cocrystallization and obtaining cocrystalline products with no traces of their starting components.
Rapid Expansion of Supercritical Solvents. The Rapid Expansion of Supercritical Solvents (RESS) technique
consists of the saturation of the supercritical fluid (supercritical CO 2 ) with a solid substrate (API and coformer in the case of producing cocrystals) prior to the depressurization of the CO 2 phase through a nozzle into a drying chamber at atmospheric pressure. Mullers et al. have used this process to produce microparticles of ibuprofen-nicotinamide cocrystals. 83 The main drawback of this technique is that the starting components (API and coformer) have to be soluble in supercritical CO 2 , as unfortunately most pharmaceutical molecules have a very low solubility in it.
2.3.3. Supercritical Antisolvent Cocrystallization. Using supercritical CO 2 as an antisolvent for cocrystallization works on the principle that solubility of API and the coformer is reduced in supercritical CO 2 , allowing them to precipitate together in a cocrystalline structure. This approach has the potential to control the polymorphic form of the API or cocrystals produced. 82, 84, 85 It has been used for the production of cocrystals by two distinct techniques: (1) a batch gas antisolvent (GAS) process which involves saturating a solution containing the dissolved API and coformer inside a high pressure vessel with CO 2 until cocrystallization occurs 82, 84 and (2) a semicontinuous supercritical antisolvent (SAS) process which involves forcing a solution containing the dissolved API and coformer molecules through a nozzle into a high pressure vessel containing supercritical CO 2 . 80 In both techniques, the CO 2 dissolves in the solvent simultaneously expanding its volume and reducing it solubilizing ability, ultimately resulting in precipitation. Ober and Gupta demonstrated GAS in the formation of itraconazole-succinic acid cocrystals and compared the properties of the cocrystals thus formed, to those formed from conventional solution antisolvent cocrystallization. 84, 86 Cocrystal structure and habit were equivalent from both preparation methods, but agglomeration properties were modified. GAS resulted in the formation of rosette type agglomerates which demonstrated an enhanced dissolution profile relative to the spherulite agglomerates formed from liquid antisolvent. Padrela et al. demonstrated the SAS process for the formation of micron-sized needle and block-shaped particles of indomethacin-saccharin cocrystals. 80 Other authors have used the SAS process to produce naproxen-nicotinamide and diflunisal-nicotinamide cocrystals and have observed the CO 2 /solution flow ratio to have paramount importance in the production of cocrystal-pure powders.
86,87 (Figure 6 ). This is a single-step process which consists of spraying a solution containing the dissolved starting cocrystal components through a nozzle with supercritical CO 2 into a drying chamber at atmospheric pressure. Padrela et al. have used the Supercritical Enhanced Atomization (SEA) technique to produce micro-to nanosized cocrystals of theophylline with several coformers and fine-tune the cocrystal particles' morphology and dissolution properties. 88, 89 Interestingly, this technique was also successfully used to generate microcomposites of theophylline-saccharin cocrystals dispersed in hydrogenated palm oil as a controlled release formulation. 90 The above methods represent the majority of standard approaches to cocrystal formation and are summarized in Table 1 . Recently emerging preparation methods, which are relatively uncommon, are reviewed in section 2.4.
2.4. Miscellaneous Cocrystal Preparation. 2.4.1. Laser Irradiation. This method consists of using a high-power CO 2 laser to irradiate powder blends of cocrystal formers and induce their recrystallization to a cocrystal structure. Titapiwatanakun et al. have used this method to produce caffeine cocrystals with oxalic acid and malonic acid. 91 Interestingly, these authors have found that the cocrystal formers need to sublime to a considerable extent for the cocrystallization to take place, which indicated that the mechanism of the molecular rearrangement between API and coformer molecules and the nucleation of the cocrystal is likely to take place in the vapor phase.
2.4.2. Electrochemically Induced Cocrystallization. Urbanus et al. demonstrated the potential of using cocrystallization combined with electrochemistry for in situ product removal of carboxylic acids. 92 Proof-of-principle was established using a cinnamic acid and 3-nitrobenzamide cocrystal system. This work showed that electrochemistry can be used to locally shift the pH to obtain neutral carboxylic acids and generate a local driving force for cocrystallization.
2.4.3. Resonant Acoustic Mixing. Resonant acoustic mixing has been used to mix the target molecule and coformer in the presence of a liquid to form a cocrystal in the absence of any grinding media. In this method, mechanical energy is transferred acoustically into a wetted powder mixture, encouraging intimate mixing of the components. A range of carbamazepine cocrystals were successfully produced using a labRAM resonant acoustic mixer operating at 80−100G and 60 Hz. The cocrystal products were isolated at a range of laboratory scales, 100 mg and 1.5 and 22 g, and the technology appeared amenable to scale-up. 93 2.4.4. Spray Drying. Spray drying is a continuous single-step method of transformation of liquids (solutions, suspensions, slurries) to solid powders. 94−96 It is advantageous due to its continuous, highly controllable, and fast process. Although spray drying has been widely used in formulating amorphous solid dispersions because of the fast solidification process, it has also been employed in synthesis of cocrystals. 97 Alhalaweh and Velaga spray dried several combinations of API-coformer with the aim of cocrystallization. They claim that cocrystallization has been observed in highly supersaturated regions of the drug due to the rapid solvent evaporation, presence of the coformer, or interaction between the drug and coformer in liquid form. 98 Another application of spray drying to generate pharmaceutical cocrystals was done to prepare the carbamazepine−nicotinamide cocrystal (CNC; 1:1). Also, it was proved that TPD can be used for the formation of cocrystals by industrially feasible spray drying methods. 99 Spray drying can also be used to produce cocrystals embedded in an excipient matrix with enhanced rheological properties. Walsh et al. have demonstrated the production of cocrystals (sulfadimidine as the poorly soluble model API and 4-aminosalicylic acid as the coformer) by spray drying in the presence of a third component (excipient matrix). 100 It was found that a larger difference in HSP (Hansen Solubility Parameters) between the cocrystal components and the excipient promotes cocrystal formation during spray drying in the presence of a carrier excipient, as the cocrystal components will not be miscible with the excipient. This leads to the cocrystal components (API and coformer) remaining phase separated from the excipient but still interacting/cocrystallizing with each other, generating a cocrystal phase embedded in excipient matrix. The compaction properties of these cospray dried (sulfadimidine and 4-aminosalicylic acid with excipient) cocrystal systems were notably improved compared to the spray dried (sulfadimidine and 4-aminosalicylic acid without excipient) cocrystals, due to less sticking characteristics.
2.4.5. Freeze-Drying. Freeze-drying, technically known as lyophilization, has been mostly used as a processing technique to preserve a wide variety of products, which include food and pharmaceuticals. This process works by freezing the material and then reducing the surrounding pressure to allow the frozen water in the material to sublime directly from the solid phase to the gas phase. It has also has been demonstrated recently to be a feasible method for the preparation of new solid forms of cocrystal systems. 101 Eddleston et al. prepared a new form of the theophylline:oxalic acid cocrystal using freeze-drying. Cocrystallization takes place via an amorphous phase that is generated as solvent sublimes during the freeze-drying process.
2.4.6. Electrospray Technology. Electrospraying is a process of simultaneous droplet generation and charging by means of an electric field. In this process, a solution containing the dissolved substances flows out from a capillary nozzle, which is maintained at high potential, through an electric field, which causes elongation of the solution droplets to form a jet. The solution jet is dried, and the generated particles are collected on a charged powder collector. Patil et al. demonstrated the potential of this process to generate cocrystals of carbamazepine and itraconazole with different coformers. 102 
COCRYSTAL APPLICATION AREAS
Cocrystal formation results in a new crystal structure, which is entirely independent from any of the starting materials. This new crystal structure imparts a new set of physical properties, also independent of and indifferent to the physical properties of any of the starting materials. Currently, the crystal structure and resulting physical properties of a cocrystal cannot be predicted from any property of the starting materials. As a result of potential physical property improvements, cocrystal applications are many and continue to grow.
3.1. Solubility. By far the most prolific utility of cocrystals to date has been to improve the solubility of the starting material, particularly when that starting material is an active pharmaceutical ingredient. Low aqueous solubility is a barrier to satisfactory drug delivery and, as such, often prevents a medicine from being fit for its purpose. Inherently, a cocrystal will have a different solubility than that of either of the starting materials due to the altered underlying crystal structure. The solubility alteration can be in either direction. Enhanced solubility is desirable, as it will improve the bioavailability of the drug, but excessive enhancement can be problematic as it can lead to undesirable precipitation of the starting material due to the generation of a supersaturated solution. 23 This has been characterized for cocrystal materials as a "spring and parachute" effect 103 ( Figure 7 ).
Zheng et al. reported improved solubility of resveratol upon cocrystallization with 4-aminobenzaamide and isoniazid. 104 Hu et al. demonstrated an increase in aqueous solubility from 7.5 mg/L febuxostat to 571 mg/L for a febuxostate:arginine cocrystal, 105 showcasing the potential physical property modification that can be achieved with cocrystals. Perlovich and coauthors demonstrated that cocrystals can improve or reduce solubility as a function of the coformer for 4 aminosalicyclic acid. 106 Cocrystallization with isoniazid, caffeine, pyranzinamide, nicotinamide, and isonicotinamide resulted in cocrystals (sometimes hydrated) which increased aqueous solubility at pH 2.0 by at least a factor of 2, while cocrystallization with theophylline was found to reduce the solubility by half in the same solution. This was due to partial cocrystal disintegration back to original starting materials in solution.
There are many other accounts of improved solubility upon cocrystal formation available in the literature, but it is worth recalling the true nature of solubility as we consider the cocrystal solubility impact. Solubility is a thermodynamic measure of the amount of a solute that can be contained in a given volume of solvent at fixed conditions (temperature and pressure). The presence of impurities in the solvent or solute will affect solubility measurements. In the case of cocrystals, the coformer can be considered as an impurity and therefore be expected to alter the solubility of the starting material. This is often not accounted for in reported solubility measurements where cocrystal solubility is compared to the starting material solubility in the pure solvent. To compare like with like, it is more accurate to compare the solubility of the cocrystal with the solubility recorded for the equivalent physical mixture, or at least in the presence of some known concentration of the coformer. The expected impact of the coformer on cocrystal solubility is lacking in the majority of published accounts. An extensive study by Pastore et al. addressed this exact issue in 2015 by comparing the solubility, dissolution, and permeability characteristics of raw carbamazepine with three of its cocrystals (vanillin, succinc acid, and nitropyridine N-oxide) and their respective physical mixtures. The authors concluded that the physical mixtures were distinct from the cocrystal material verifying the pharmacological impact of cocrystal materials. 107 The collective work of Rodriguez-Hornedo has also extensively addressed cocrystal solubility and has proposed the concept of a solubility product, K sp , which takes into account the relative concentrations of both cocrystal formers during cocrystal dissociation in a solvent.
when activity coefficients are taken as unity; superscripts refer to the stoichiometric number of molecules of a/b in the cocrystal. The solubility product reflects the strength of cocrystal solid state interactions of the drug and ligand relative to interactions with the solvent and is also correlated to solubility, with a higher K sp indictaing higher cocrystal solubility. 109 3.2. Bioavailability. Cocrystals bear the potential to enhance the delivery and clinical performance of drug products by modulating drug solubility, pharmacokinetics, and bioavailability. Particularly, using cocrystals to improve oral drug absorption of BCS class II and IV drugs has been a strong focus of several case studies published in the literature. Stanton et al. have compared the improvement on the solubility and pharmacokinetics of AMG 517, a potent and selective transient receptor potential vanilliod 1 (TRPV1) antagonist, when cocrystallizing this drug with carboxylic acid (cinnamic acid and benzoic acid and amide coformers (cinnamamide and benzamide)). 110 All four AMG517 cocrystals showed faster intrinsic and powder dissolution rates in fasted simulated intestinal fluid than the free base of AMG 517. The results on the pharmacokinetics showed a 2.4-to 7.1-fold increase in the area under the concentration−time curve in rat PK investigations, which highlights the improvement in bioavailability of AMG 517 when in a cocrystalline form. Other studies have demonstrated the efficiency of cocrystallization in improving the solubility and bioavailability of poorly soluble APIs such as indomethacin, 111 baicalein, 112 and quercetin. 113 Interestingly, polymers and other excipients can provide a huge contribution to improving the bioavailability of cocrystals by acting as crystallization inhibitors and prolonging the supersaturation concentration of cocrystals during dissolution. This approach is particularly important in situations where the cocrystal transforms rapidly to a low-solubility form of the drug and is unable to maintain desired solubility levels necessary to ensure optimal absorption. Childs et al. improved the solubility and bioavailability of a danazol:vanillin cocrystal by using an appropriate formulation containing a combination of cocrystal, a solubilizer (1% vitamin E-TPGS (TPGS)), and a precipitation inhibitor (2% Klucel LF Pharm Hydroxypropyl- . 114 This formulation resulted in a high improvement in the bioavailability of the cocrystal by over 10 times compared to the poorly soluble danazol polymorph. Another example of cocrystals that undergo rapid precipitation during dissolution and form a dihydrate form of the parent drug in aqueous media is dihydromyricetin-caffeine and dihydromyricetin-urea cocrystals. Wang et al. have improved the bioavailability of these cocrystals by inhibiting the precipitation of dihydromyricetin using polyvinylpyrrolidone K30 as a crystallization inhibitor. 115 Approximately 5-fold enhancement in oral bioavailability of dihydromyricetin was achieved when both cocrystals were dosed with 2.0 mg/mL polyvinylpyrrolidone K30 solution compared to dihydromyricetin dihydrate suspended in a similar same dissolution medium.
3.3. Controlled Release. Cocrystallization provides an opportunistic approach to modulate the physicochemical properties of pharmaceutical drugs, which include solubility and dissolution rate. Particularly, depending on the coformer that cocrystallizes with the API, the dissolution rate of the API in water or a buffer solution can be increased or decreased over time. Carbamazepine−cinnamic acid cocrystals synthesized by solvent evaporation showed a higher dissolution rate, solubility, and stability in water compared to carbamazepine. 116 Arenas-Garcia et al. produced several cocrystals of acetazolamide (ACZ) with enhanced intrinsic dissolution rates when compared to pure ACZ in a medium simulating physiological conditions (HCl 0.01N, pH 2.0). 117 The cocrystals which provided the largest dissolution rates were those which showed the poorest solid-state stability in the same medium by initially undergoing solvent mediated phase transformation.
Cocrystals also bear the potential to reduce the dissolution rate of the original APIs. Chen et al. used the cocrystallization approach to sustain the dissolution behavior of ribavirin, a water-soluble antiviral drug. 118 These authors demonstrated that the release rate of ribavirin can be manipulated over a wide range by the formation of cocrystals, which may subsequently help lower its peak-to-trough fluctuation in plasma concentrations.
Padrela et al. used a supercritical fluid enhanced atomization (SEA) process, which is a nanospray drying method that uses the atomization potential of supercritical CO 2 to disperse and dry a drug solution through a coaxial nozzle, to produce microto nanosized cocrystals of theophylline with several coformers. 119 The authors found that the solubility of each coformer in the dissolution medium (phosphate-buffered saline, pH 7.4 at 25•C) could determine the dissolving rate behavior of the produced cocrystals. Consequently, low-soluble coformers provided TPL cocrystals with slow-dissolving rates, while highly soluble coformers provided faster-dissolving TPL cocrystals.
Tiago et al. reduced the dissolution behavior and improved the solid state stability of theophylline by generating cocrystals of this drug with saccharin dispersed in a lipid using the SEA process. 90 The dissolution of theophylline was further improved when theophylline-saccharin cocrystals (TPL-SAC) were formed and dispersed in hydrogenated palm oil (HPO) during the SEA processing. The SEA process provided improvement of TPL stability and delivery by single-step micronization, cocrystallization, and encapsulation. Depending on the ratio of TPL-SAC to HPO, the dissolution rate of TPL could be further sustained over time with increasing proportions of HPO in the TPL-SAC-HPO microcomposites.
In addition to this, the TPL-SAC-HPO microcomposite particles were able to attenuate the TPL burst effect.
The presence of polymers in the dissolution media might also impact the supersaturation level and dissolution rate of cocrystals. Guo et al. have studied the impact that the presence of different polymers (polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), and polyvinylpyrrolidone/vinyl acetate (PVP-VA)), which have been predissolved in a solution medium, has on the dissolution behavior of flufenamic acid− theophylline (FFA-TPL) and flufenamic acid−nicotinamide (FFA-NCT) cocrystals. 120 It was demonstrated that by controlling the dissolution environment with the presence of certain polymers, such as PVP or PVP-VA, which can interact with the crystal surface to alter its dissolution properties, the solubility and dissolution rates of FFA-TPL and FFA-NIC cocrystals is significantly improved.
3.4. Multidrug Cocrystals. Combining multiple active pharmaceutical ingredients (APIs) into one unit dose has become a popular trend in the drug formulation industry. The need to target multiple receptors for effective treatment of complex disorders such as HIV/AIDS, cancer, and diabetes in addition to the increasing demand for facilitating the reduction of drug manufacturing costs are the two main reasons for this growing trend. Salts, mesoporous complexes, coamorphous systems, and cocrystals are systems which have been used for combining multiple APIs in a single delivery system. 121 Multidrug cocrystals (MDCs) are advantageous compared to coamorphous systems in terms of their enhanced stability and in terms of their reduced payload compared to the mesoporous and cyclodextrin complexes. Thipparaboina et al. defined the MDCs as "dissociable solid crystalline supramolecular complexes comprising two or more therapeutically effective components in a stoichiometric ratio within the same crystal lattice, wherein the components may predominantly interact via nonionic interactions and rarely through hybrid interactions (a combination of ionic and nonionic interactions involving partial proton transfer and hydrogen bonding) with or without the presence of solvate molecules." 122−124 MDC could offer potential advantages compared to the pure drug components, such as enhanced solubility and dissolution of at least one of the components, 125, 126 enhanced bioavailability, 78 improved stability of unstable APIs via intermolecular interactions, 127, 128 and increased mechanical strength and flowability. MDC formulation of ethenzamide and gentinsic acid was reported with an improved intrinsic dissolution rate. Meloxicam and aspirin containing MDC was developed with a 12-times decrease in the time to reach the therapeutic concentrations and 4-fold bioavailibity enhancement. An extensive list of MDCs can be found elsewhere. 129 On the other hand, there are examples of MDCs with lower intrinsic dissolution rates compared to pure APIs. Kaur et al. reported the MDC of two anticonvulsants, lamotrigine and phenobarbital. The two molecules form heterodimers through hydrogen binding. Dissolution studies in phosphate buffer (pH 7.2) revealed the decreased dissolution rate of cocrystals in the order of pure phenobarbital > pure lamotrigine > cocrystal. 130 So far, no computational approach has been developed for predicting and/or screening of MDC formulations. Thus, prediction and screening of the potential MDC formulations mostly follows the knowledge-based approach, which includes hydrogen-bond tendency, pK a studies, use of synthons, and molecular descriptors. Synthon engineering is all about studying the structural units within the supermolecules that
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Review are capable of forming intermolecular interactions. Carboxylic acid dimers, acid-pyridine, phenol-pyridine, and phenolcarboxylic acid are the most frequently seen synthons. 131 Moreover, the Cambridge Structural Database (CSD) could be used to screen the possible hydrogen bondings and synthon competitions. 132 pK a was used as a simple tool for the prediction of cocrystal formation. It was shown that generally a difference between pK a base and pK a acid (ΔpK a ) > 3 leads to the formation of salts, while ΔpK a < 0 results in cocrystal formation. More modifications have been made to the use of ΔpK a as a measure of cocrystal formation by Cruz Cabeza et al., where they studied 6465 crystalline structures in CSD and validated and measured their ΔpK a . They found a linear relationship between the possibility of proton transfer between acid−base pairs and the ΔpK a . 133 The main techniques of cocrystal synthesis have been used for preparing MDCs as well. These techniques include distillation, solvent evaporation, neat and liquid-assisted grinding, slurry reaction, melting, and cooling crystallization. Scale-up techniques such as spray-drying, 99 hot melt extrusion, 134 twin screw extrusion, 51 and high shear granulation 63 have been used for scale-up production of cocrystals. The MDC formulation approach has been evolved a lot from exploring different combinations of APIs, yet more efforts are required for selection for therapeutically relevant APIs that could be beneficial to the patients and pharmaceutical industry. Moreover, more efforts are required in terms of predictive modeling of the cocrystallization process of two APIs.
3.5. Mechanical Properties Enhancement. Tableting is the most popular pharmaceutical dosage form due to its numerous technical and economic advantages. Low manufacturing cost; high production throughput; and ease of consumption, storage, and handling are some of these benefits. 135 However, several deficiencies caused by poor flowability and mechanical properties have always been a difficulty along the way to successful tablet production.
Several strategies have been employed to address these issues during the formulating process of APIs. Adding silicon dioxide for increasing mechanical strength of tablets and magnesium stearate for improved flowability are some of these techniques. Cocrystallization has been also investigated as a technique to improve chemical and physical properties of powders including mechanical strength and flow properties. For instance, compression properties of paracetamol form I have been improved by cocrystallization with theophylline, oxalic acid, naphthalene, and phenazine. 136 Hiendrawan et al. obtained cocrystals of paracetamol and 5-nitroisophtalic acid using the solvent evaporation method. The tableting experiments showed that the formed cocrystal has superior tabletability properties compared to both paracetamol and the coformer. 137 The carbamazepine and saccharin cocrystal was shown to be denser compared to pure carbamazepine. Moreover, higher tensile strength compared to pure carbamazepine was obtained at any compaction pressure. Heckel analysis of the carbamazepine and cocrystal revealed that plastic deformation in the cocrystal was started at lower compression, leading to higher compaction. 138 3.6. Taste Masking. Quick disintegrating tablets with rapid dissolution are required for preparing oral disintegrating tablets. This strategy enables the use of tablets without the need for chewing or water intake, which broadens the spectrum of the drug users to geriatric, pediatric, and traveling patients with no access to water. However, readily disintegrating tablets necessitate the use of taste masking agents to improve the patients' experience. So far, the use of sugar-based excipients has been the main approach. On the other hand, poor dissolution rate can be another limiting factor in developing oral disintegrating formulations. Thus, a greater advantage could be achieved using an approach for improving dissolution with tablet sweetening agents.
Cocrystallization could be a promising strategy for improving the dissolution rate using sugar-based coformers. Arafa et al. have done so by using sucralose as a coformer for preparing cocrystals of hydrochlorothiazide. The produced cocrystal got the benefits of increased dissolution rate and taste masking, simultaneously. 139 Maeno et al. reported a new cocrystal of paracetamol with trimethylglycine (TMG) with improved tabletability, compression, and dissolution properties. Moreover, the taste sensing experiments revealed the sweetness of the formulation due to the presence of TMG in the structure. 140 Theophelline is known for its bitter taste; hence, current marketed solid and oral formulations have been formulated using artificial sweeteners such as vanilla, sodium glutamate, sodium saccharin, and d-sorbitol. A 1:1 stoichiometric cocrystal of theophelline and saccharine was prepared via liquid assisted grinding. The prepared cocrystal showed enhanced dissolution and sweetness at the same time based on the automated sweetness tasting machine used in this study. 141 Nine cocrystals of propiverine were generated by mixing it with organic acid solutions. The results of the use of a taste sensor showed that propiverine salicylic acid cocrystals are less bitter than propiverine hydrochloride. The authors illustrated both improved aqueous solubility and taste masking, simultaneously. 142 3.7. Enabling in Process Separation and Purification. Lee et al. demonstrated a continuous cocrystallization process at 90 mL/min scale for the manufacture of phenazine−vanillin cocrystals for the purpose of preferentially separating vanillin from its mother liquor. 143 Billot et al. reported on an slurry based method for the manufacture of an API cocrystal at pilot plant scale to provide for purification of the API, with subsequent cleavage of the cocrystal to release the API product also demonstrated. Intellectual property (IP) is vital for pharmaceutical companies. IP protection of new ideas, inventions, processes, or products enables the exclusivity on the manufacture and commercialization of pharmaceutical services or products. IP is protected in law by, for example, patents, copyright, and trademarks, which enable individuals or organizations/ companies to earn recognition or financial benefit from their own work or investment in a creation. Specifically, patents are a recognition for an invention, which must satisfy the criteria of global novelty, nonobviousness, and industrial or commercial application. Patent life cycle management of drugs or drug products is a critical activity that pharmaceutical companies have to deal with to ensure they keep their drugs in the market as long as possible.
Screening of novel solid forms of marketed drugs, including polymorphs, salts, and cocrystals provides the opportunity to grant new IP on those drugs and extend their patent life cycle. 144 Pharmaceutical cocrystals possess regulatory and IP advantages which confer them with unique opportunities, advantages, and challenges. 145, 146 FDA has recently issued revised draft guidance on the classification of pharmaceutical Crystal Growth & Design Cryst. Growth Des. XXXX, XXX, XXX−XXX cocrystals for industry, which states that from a regulatory perspective, drugs designed to contain a new cocrystal are considered analogous to a new polymorph of the API. This guidance takes novel cocrystals to be considered as new drug substances rather than drug product intermediates, which promotes their independent patentability as novel solid forms. Cocrystals bear also the potential to provide meaningful IP extension to existing drugs in the market after the expiration of the original patent, playing an important role in drug lifecycle management. Figure 8 shows an increasing trend in patent submissions for novel cocrystals and cocrystal preparation methods between 2004 and 2017.
Cocrystals also possess important scientific advantages. Some of these advantages link to the availability of a wide number of potential complementary molecules (coformers) to cocrystallize with the drug molecules. This maximizes the number of new cocrystals that might be discovered for a particular drug with suitable physicochemical properties (e.g., solubility, bioavailability, physical stability). 2 As neither of the APIs of coformers needs to have ionizable functional groups in their molecular structures, which is a prerequisite for salt formation, this opens up a larger array of possibilities for the generation of novel solid state forms of APIs as cocrystals. That in turn promotes the possibility for IP extension of the existing drugs currently in the market.
CONCLUSIONS
Cocrystallization offers one of the most promising approaches to improve physicochemical properties of APIs. A wide range of options exist to prepare cocrystals ranging from routine lab scale synthesis methods to potentially large scale continuous production methods. This review offers standard descriptions and examples of established and emerging cocrystal preparation routes. Moreover, detailed insight is given on the proposed mechanisms of cocrystallization in different techniques. As cocrystals continue to gain interest and prove their value, the range of demonstrated cocrystal application areas continues to expand. All demonstrated application areas for pharmaceutical cocrystals are included in this review with the aim of highlighting the wide ranging potential of these materials. It is anticipated that cocrystals will become more and more routine in pharmaceutical development as their benefits continue to be demonstrated and routine routes of manufacturing are proven.
